FDA Approved: Yes (First approved May 15, 2020)
Brand name: Qinlock
Generic name: ripretinib
Dosage form: Tablets
Company: Deciphera Pharmaceuticals, Inc.
Treatment for: Gastrointestinal Stromal Tumor
Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
INDICATIONS AND USAGE
QINLOCK is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Recommended Dosage: 150 mg orally once daily with or without food
WARNINGS AND PRECAUTIONS
- Palmar-Plantar Erythrodysesthesia Syndrome: Based on severity, withhold QINLOCK and resume at same or reduced dose.
- New Primary Cutaneous Malignancies: Perform dermatologic evaluations when initiating QINLOCK and routinely during treatment.
- Hypertension: Do not initiate QINLOCK in patients with uncontrolled hypertension and monitor blood pressure during treatment. Based on severity, withhold QINLOCK and then resume at same or reduced dose or permanently discontinue.
- Cardiac Dysfunction: Assess ejection fraction by echocardiogram or MUGA scan prior to initiating QINLOCK and during treatment, as clinically indicated. Permanently discontinue QINLOCK for Grade 3 or 4 left ventricular systolic dysfunction.
- Risk of Impaired Wound Healing: Withhold QINLOCK for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of QINLOCK after resolution of wound healing complications has not been established.
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
 tablets, for oral use FDA Approved: Yes (approved May 15, 2020)){kind=link}
0 Comments